Voltage‑Gated Calcium Channel (VGCC) Type N Antibody
Also known as: N-VGCC, NCC
Use
N‑type calcium channel antibodies are more highly associated with primary lung cancer than P/Q‑type. One or all of the autoantibodies in the myasthenia gravis (MG)/LEMS evaluation can occur with neoplasia without evidence of neurological impairment. One or both calcium channel antibodies (P/Q and N) can occur with paraneoplastic and idiopathic cerebellar ataxia, encephalomyeloneuropathies, and autonomic neuropathy. Classical symptoms of LEMS include proximal muscle weakness, fatigability, dry mouth and impotence. When presentation is further complicated with oculobulbar weakness, these symptoms can easily be misinterpreted as MG. However, because VGCC antibodies are positive in only approximately 5% of MG patients, the measurement of these antibodies is very useful in distinguishing LEMS from MG.
Special Instructions
Not provided.
Limitations
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Methodology
Immunoassay (RIA)
Biomarkers
Voltage‑Gated Calcium Channel N‑type Antibody
Protein
Result Turnaround Time
7-14 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL serum
Minimum Volume
0.5 mL
Container
standard transport tube
Collection Instructions
Serum separator tube; centrifuge and transfer serum
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 48 hours |
| Frozen | 60 days |
Other tests from different labs that may be relevant
